DDInter1961 DDInter927
A dideoxynucleoside compound in which the 3&#39;-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia. [PubChem]
Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent . Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with high mortality rates and low therapeutic response from standard chemotherapies in relasping conditions. In a randomized trial, inotuzumab ozogamicin displayed higher percentages of patients undergoing longer periods of complete remission with no evidence of disease in comparison to patients receiving alternative chemotherapy .
Zidovudine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Trifluridine
Zidovudine {u} (Compound) resembles {v} (Compound) Idoxuridine
Zidovudine {u} (Compound) resembles {v} (Compound) Telbivudine
Zidovudine {u} (Compound) treats {v} (Disease) acquired immunodeficiency syndrome
Zidovudine {u} (Compound) binds {v} (Gene) UGT2B7
Zidovudine {u} (Compound) upregulates {v} (Gene) THAP11
Zidovudine {u} (Compound) is included by {v} (Pharmacologic Class) Nucleoside Reverse Transcriptase Inhibitors
Zidovudine {u} (Compound) downregulates {v} (Gene) MRPS16
Zidovudine {u} (Compound) causes {v} (Side Effect) Tremor
Zidovudine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cimetidine
Zidovudine may cause a moderate interaction that could exacerbate diseases when taken with Trifluridine
Zidovudine (Compound) resembles Idoxuridine (Compound)
Zidovudine (Compound) resembles Telbivudine (Compound)
Zidovudine (Compound) treats acquired immunodeficiency syndrome (Disease)
Zidovudine (Compound) binds UGT2B7 (Gene)
Zidovudine (Compound) upregulates THAP11 (Gene)
Zidovudine (Compound) is included by Nucleoside Reverse Transcriptase Inhibitors (Pharmacologic Class)
Zidovudine (Compound) downregulates MRPS16 (Gene)
Zidovudine (Compound) causes Tremor (Side Effect)
Zidovudine may cause a minor interaction that can limit clinical effects when taken with Cimetidine